Skip to content

SELLAS Life Sciences Group, Inc. SLS Change in Lease Liabilities

Change in Lease Liabilities at other companies

Immunome logo
ImmunomeIMNM
-$161K-160%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
-$2.03M+34.9%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
-$434K-53.4%
Moderna logo
ModernaMRNA
-$7M-40.0%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Revenue-
Gross profit-
Operating income-$9.3M-52.6%
Net income-$8.4M-44.6%
EPS (diluted)-$0.05+28.6%

Balance sheet

See full
Cash & equivalents$107.1M+277%
Total debt$871.0K+0.1%
Total equity$107.4M+287%
Total assets$114.2M+227%

Cash flow

See full
Operating cash flow-$8.8M+2.5%

Valuation

See full
Market cap$1.78B+674%
Enterprise value$1.68B+826%

Profitability

See full
Gross margin90%-7.4pp
Operating margin-4,195%-4,591pp
Net margin-4,130.1%-4,444pp
FCF margin-300.5%

Returns & leverage

See full
Return on equity-43.6%-17.9pp
Debt / equity0.0×
Current ratio17.2×+12.6×

Where this comes from

Reported directly by SELLAS Life Sciences Group, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: SELLAS Life Sciences Group, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about SELLAS Life Sciences Group, Inc.'s change in lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SELLAS Life Sciences Group, Inc.'s change in lease liabilities?
SELLAS Life Sciences Group, Inc. (SLS) reported change in lease liabilities of -$159K in Q1 2026.
How has SELLAS Life Sciences Group, Inc.'s change in lease liabilities changed year-over-year?
SELLAS Life Sciences Group, Inc.'s change in lease liabilities decreased by 0.0% year-over-year, from -$159K to -$159K.
What is the long-term trend for SELLAS Life Sciences Group, Inc.'s change in lease liabilities?
Over 3 years (2022 to 2025), SELLAS Life Sciences Group, Inc.'s change in lease liabilities has grown at a 10.5% compound annual growth rate (CAGR), from -$471K to -$635K.
What does change in lease liabilities mean?
Cash payments for operating leases reducing the lease liability, partially offset by new lease commencements.